LXRX Stock News & Catalysts – Lexicon Pharmaceuticals

FEATURED

New Data at 2026 American Heart Association Scientific Sessions Highlight Cardiovascular Effects of Sotagliflozin on Thrombus Formation and in Hypertrophic Cardiomyopathy

New

-- In a randomized crossover study, sotagliflozin significantly reduced ex vivo thrombus formation from baseline under both arterial and venous flow conditions -- -- Study in living human heart tissue indicate

Summary

Nov 9, 2026, 8:30 AM ·Globe Newswire

RECENT

Lexicon Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Clinical Updates

Phase 3 SONATA-HCM study substantially overenrolled; top-line data expected Q1 2027 Positive STENO1 safety data strengthens benefit-risk profile for ZYNQUISTA® NDA resubmission Phase 1 clinical development of LX9851

Nov 5, 2026, 7:00 AM ·Globe Newswire

Lexicon Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026

THE WOODLANDS, Texas, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), a leading cardiometabolic biopharmaceutical company, today announced the Company will release its third quarter

Oct 29, 2026, 8:30 AM ·Globe Newswire

Lexicon Pharmaceuticals Provides Update on Baseline Patient Characteristics for Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Hypertrophic Cardiomyopathy

-- Patient demographics consistent with prior studies of other agents in HCM and reflect real-world clinical practice -- -- Mean baseline KCCQ-CSS of 59 shows considerable symptom burden at study entry –

Oct 23, 2026, 8:30 AM ·Globe Newswire

Lexicon Pharmaceuticals Announces Publication of New Research Highlighting Sotagliflozin’s Biological Effects in Cardiovascular Disease

-- Preclinical study demonstrates positive effects of sotagliflozin on cardiac function and structure in hypertrophic cardiomyopathy -- -- Second preclinical study shows inhibitory effects of sotagliflozin on platelet

Oct 21, 2026, 8:30 AM ·Globe Newswire

Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences

THE WOODLANDS, Texas, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that company management will present at three upcoming investor conferences taking place in New

Sep 1, 2026, 4:05 PM ·Globe Newswire

Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure

THE WOODLANDS, Texas, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced results from a post hoc analysis of the Phase 3 SOLOIST-WHF trial evaluating the efficacy and safety

Aug 31, 2026, 8:30 AM ·Globe Newswire

Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851

LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders Lexicon is eligible to receive up to $1 billion in total upfront

Aug 24, 2026, 8:30 AM ·Globe Newswire

Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

Enrollment complete in Phase 3 SONATA-HCM study; top-line data expected Q1 2027 NDA resubmission activities for ZYNQUISTA® in type 1 diabetes nearing completion Phase 1 clinical development of LX9851 ongoing by Novo

Aug 6, 2026, 7:30 AM ·Globe Newswire

Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026

THE WOODLANDS, Texas, July 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced the Company will release its second quarter 2026 financial results on Thursday, August 6, 2026, prior

Jul 30, 2026, 8:30 AM ·Globe Newswire

Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM)

Study substantially exceeded enrollment target of 500 patients Topline results anticipated in Q1 2027 THE WOODLANDS, Texas, July 27, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today

Jul 27, 2026, 8:30 AM ·Globe Newswire

Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions

THE WOODLANDS, Texas, June 03, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that it will present data from clinical studies of sotagliflozin in Type 1 diabetes (T1D) and

Jun 3, 2026, 8:00 AM ·Globe Newswire

Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference

THE WOODLANDS, Texas, May 28, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that Company management will participate in a fireside chat at the 2026 Jefferies Global Healthcare

May 28, 2026, 8:30 AM ·Globe Newswire

Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference

THE WOODLANDS, Texas, May 12, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that Company management will participate in a fireside chat at the 4th Annual H.C. Wainwright

May 12, 2026, 8:30 AM ·Globe Newswire

Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates

SONATA-HCM anticipated to be fully enrolled mid-2026 Resubmission of NDA for ZYNQUISTA® in type 1 diabetes anticipated mid-2026 with potential for approval this year Clinical development of LX9851 initiated by

May 7, 2026, 7:30 AM ·Globe Newswire

Lexicon Pharmaceuticals, Inc. LXRX · News